Distribuzione geografica
Continente #
EU - Europa 2.777
NA - Nord America 2.730
AS - Asia 1.071
Continente sconosciuto - Info sul continente non disponibili 8
SA - Sud America 7
AF - Africa 2
Totale 6.595
Nazione #
US - Stati Uniti d'America 2.715
IE - Irlanda 932
CN - Cina 727
UA - Ucraina 628
SE - Svezia 432
IT - Italia 277
FR - Francia 149
IN - India 140
DE - Germania 138
FI - Finlandia 109
TR - Turchia 99
KR - Corea 77
GB - Regno Unito 54
AT - Austria 24
CA - Canada 13
BE - Belgio 12
VN - Vietnam 12
EU - Europa 8
RU - Federazione Russa 6
JP - Giappone 5
BR - Brasile 4
NL - Olanda 4
CH - Svizzera 3
ID - Indonesia 3
CZ - Repubblica Ceca 2
ET - Etiopia 2
IR - Iran 2
MX - Messico 2
PL - Polonia 2
SA - Arabia Saudita 2
CL - Cile 1
CO - Colombia 1
DK - Danimarca 1
ES - Italia 1
HK - Hong Kong 1
MD - Moldavia 1
PE - Perù 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
SG - Singapore 1
TW - Taiwan 1
Totale 6.595
Città #
Dublin 932
Chandler 536
Jacksonville 428
Dearborn 325
Nyköping 291
Nanjing 203
Wilmington 102
Princeton 98
Beijing 91
Ashburn 84
Nanchang 71
Ann Arbor 70
New York 65
San Mateo 63
Des Moines 49
Shenyang 47
Hebei 44
Rome 41
Helsinki 40
Tianjin 39
Hilden 36
Woodbridge 33
Kunming 30
Pune 29
Foggia 28
Hangzhou 28
Jinan 27
Jiaxing 26
Boardman 24
Vienna 24
Changsha 18
Ningbo 17
Milan 14
Brussels 12
Dong Ket 12
Falls Church 12
San Severo 12
Zhengzhou 12
Wuhan 11
Norwalk 10
Auburn Hills 9
Bari 9
Guangzhou 9
Lanzhou 9
Washington 9
Houston 8
Redwood City 8
Hefei 7
Santeramo In Colle 7
Kocaeli 6
Los Angeles 6
Naples 6
Orange 6
Seattle 6
Changchun 5
New Delhi 5
Perugia 5
Saarbrücken 5
Taizhou 5
Caserta 4
Fuzhou 4
Philadelphia 4
Reno 4
Rockville 4
Shanghai 4
Tappahannock 4
Cassino 3
Düsseldorf 3
Genova 3
Niedernberg 3
Paris 3
Pavia 3
Pimonte 3
Saga 3
Stockholm 3
Toronto 3
Turin 3
Waterloo 3
Addis Ababa 2
Ahmedabad 2
Ancona 2
Augusta 2
Bologna 2
Borås 2
Cagliari 2
Cattolica 2
Chicago 2
Columbia 2
Haikou 2
Izmir 2
London 2
Mashhad 2
Mississauga 2
New York County 2
Padova 2
Phoenix 2
Pisa 2
Rostock 2
Scafati 2
Southend 2
Totale 4.272
Nome #
Use of mammalian target of rapamycin inhibitor for treating pathologies including neurodegenerative diseases (Alzheimer's disease), neuroinflammatory diseases and tumor diseases with neurological involvement, by intrathecal administration 164
Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the emotional reactivity of the offspring: a longitudinal behavioral study in wistar rats. 128
Social memory impairment in a triple-transgenic mouse model of Alzhemer's disease is accompained by monoaminergic alterations 116
The cannabinoid agonist WIN55212-2 normalizes levodopa-induced volume transmission unbalances across the two brain hemispheres of dyskinetic rats 110
Data available on the extent of cocaine use and dependence: Biochemistry, pharmacologic effects and global burden of disease of cocaine abusers. 105
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis 101
Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels 100
Chronic psychosocial defeat differently affects lipid metabolism in liver and white adipose tissue and induces hepatic oxidative stress in mice fed a high-fat diet 99
Mice lacking fatty acid amide hydrolase (FAAH-/-) showed increased serotonergic neurotransmission and reduced emotional reactivity 98
Glutamate and mitochondria: two prominent players in the oxidative stress-induced neurodegeneration 95
Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: Role of CB(1) and TRPV1 receptors 94
Biochemical and Neurobehavioral Profile of CHF2819, a Novel, Orally Active Acetylcholinesterase Inhibitor for Alzheimer’s Disease 93
Perinatal exposure to delta-9-tetrahydrocannabinol causes enduring cognitive deficits associated with alteration of cortical gene expression and neurotransmission in rats 92
Prenatal exposure to the cannabinoid receptor agonist WIN 55,212-2 increases glutamate uptake through overexpression of GLT1 and EAAC1 glutamate transporter subtypes in rat frontal cerebral cortex 91
Antinutritional effects of fumonisin B1 and pathophysiological consequences 91
Alterations of Clock Gene RNA Expression in Brain Regions of a Triple Transgenic Model of Alzheimer’s Disease 91
Cannabinoids normalize neurochemical unbalances across the two hemispheres of dyskinetic rats 89
Preclinical progress with CHF2819, a novel orally active acetylcholinesterase inhibitor 88
Principles and therapeutic relevance for targeting mitochondria in aging and neurodegenerative diseases. 88
Prenatal exposure to low concentrations of carbon monoxide alters habituation and non-spatial working memory in rat offspring 84
Effects of early postnatal exposure to low concentrations of carbon monoxide on cognitive functions in rats 84
Monoaminergic changes in locus coeruleus and dorsal raphe nucleus following noradrenaline depletion 83
The satiety signal oleoylethanolamide stimulates oxytocin neurosecretion from rat hypothalamic neurons 81
Aberrant insulin signaling in Alzheimer's disease: current knowledge 80
Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function 79
Depressive-like behavior is paired to monoaminergic alteration in a murine model of Alzheimer's disease 79
The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs 78
Effects of prenatal exposure to low concentrations of carbon monoxide on sexual behaviour and mesolimbic dopaminergic function in rat offspring 78
Intranasal delivery of dopamine to the striatum using glycol chitosan/sulfobutylether-β-cyclodextrin based nanoparticles 78
Cannabinoid receptor 2 signaling in neurodegenerative disorders: From pathogenesis to a promising therapeutic target 78
Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer's disease by exerting anti-inflammatory and neuroprotective effects 78
Striatal 6-Ohda Lesion In Mice: Investigating Early Neurochemical Changes Underlying Parkinson's Disease 77
Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats 77
5-S-cysteinyldopamine neurotoxicity: Influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease 77
Glutamatergic alterations and mitochondrial impairment in a murine model of Alzheimer disease 75
Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer's disease 75
CHF2819: pharmacological profile of a novel acetylcholinesterase inhibitor 74
Role of the area postrema in the hypophagic effects of oleoylethanolamide 74
Biological mechanisms associated with increased perseveration and hyperactivity in a genetic mouse model of neurodevelopmental disorder 73
Novel codrugs with GABAergic activity for dopamine delivery in the brain 73
Biliverdin Reductase-A Mediates the Beneficial Effects of Intranasal Insulin in Alzheimer Disease 72
Prenatal Exposure to the CB1 Receptor Agonist Win 55,212-2 Causes Learning Disruption Associated With Impaired Cortical NMDA Receptor Function and Emotional Reactivity Changes in Rat Offspring 71
Altered expression of the CB1 cannabinoid receptor in the triple transgenic mouse model of Alzheimer's disease. 71
Evaluation of the emotional phenotype and serotonergic neurotransmission of fatty acid amide hydrolase-deficient mice 71
Brain Histamine Is Crucial for Selective Serotonin Reuptake Inhibitors' Behavioral and Neurochemical Effects 71
Inhibition of anandamide hydrolysis enhances noradrenergic and GABAergic transmission in the prefrontal cortex and basolateral amygdala of rats subjected to acute swim stress 70
Altered serotonergic function may partially account for behavioral endophenotypes in steroid sulfatase-deficient mice 70
Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: A new paradigm 69
Neurochemical and neurobehavioral effects of ganstigmine (CHF2819), a novel acetylcholinesterase inhibitor, in rat prefrontal cortex: An in vivo study 69
Altered regulation of glutamate release and decreased functional activity and expression of GLT1 and GLAST glutamate transporters in the hippocampus of adolescent rats perinatally exposed to Delta(9)-THC. 68
Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery 68
Prenatal exposure to the cannabinoid receptor agonist WIN 55,212-2 and carbon monoxide reduces extracellular glutamate levels in primary rat cerebral cortex cell cultures 65
Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2 65
The effects of oleoylethanolamide on feeding behaviour involve hypothalamic oxytocin neurons 64
Evaluation of a LC-MS method for everolimus preclinical determination in brain by using [(13)C2D4]RAD001 internal standard 64
Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer’s Disease: In Vitro and In Vivo Evidence 64
Linking lipid peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal 64
Olfactory memory is impaired in a triple transgenic model of Alzheimer disease 62
Genetic factors involved in the effects of developmental low-level alcohol induced behavioral alterations in rats 61
Role of the basolateral amygdala in mediating the effects of the fatty acid amide hydrolase inhibitor URB597 on HPA axis response to stress 60
The fat-induced satiety factor oleoylethanolamide suppresses feeding through central release of oxytocin 60
Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer's disease 60
Hindbrain noradrenergic input to the hypothalamic PVN mediates the activation of oxytocinergic neurons induced by the satiety factor oleoylethanolamide 59
Evidence for an imbalance between tau O-GlcNAcylation and phosphorylation in the hippocampus of a mouse model of Alzheimer's disease 59
Effects of ENA713 and CHF2819, two anti-Alzheimer’s disease drugs, on rat amino acid levels 57
Neurochemical changes produced by CHF2819, a novel, orally active acetylcholinesterase inhibitor, in rat brain 57
The effects of nitric oxide on striatal serotoninergic transmission involve multiple targets: An in vivo microdialysis study in the awake rat 57
Nonmotor symptoms in Parkinson's disease: Investigating early-phase onset of behavioral dysfunction in the 6-hydroxydopamine-lesioned rat model 56
Insulin signaling: An opportunistic target to minify risk of Alzheimer's disease 56
Modulation of the oxidative stress and lipid peroxidation by endocannabinoids and their lipid analogues 56
Interaction between Cognitive Reserve and Biomarkers in Alzheimer Disease 56
The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer's disease 55
From obesity resistance to obesity prediction and prevention? 55
From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases 54
Serum Albumin Is Inversely Associated With Portal Vein Thrombosis in Cirrhosis 54
Short- and long-term consequences of prenatal exposure to the cannabinoid agonist WIN55,212-2 on rat glutamate transmission and cognitive functions. 53
Delta9-Tetrahydrocannabinol increases endogenous extracellular glutamate levels in primary cultures of rat cerebral cortex neurons. Involvement of CB1 receptors 52
Astrocyte function is affected by aging and not Alzheimer's disease: A preliminary investigation in hippocampi of 3xTg-AD mice 51
Oleoylethanolamide decreases frustration stress-induced binge-like eating in female rats: a novel potential treatment for binge-eating disorder 50
Editorial: Dysmetabolism, obesity, and inflammation: Three prominent actors in the drama of major neuropsychiatric disorders 50
Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease 49
Pharmacological treatment of depression in Alzheimer's disease: A challenging task 49
Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus 48
Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats 46
Oxidative Stress in Aging Brain: Nutritional and Pharmacological Interventions for Neurodegenerative Disorders 46
TFEB activation restores migration ability to Tsc1-deficient adult neural stem/progenitor cells 45
Oxazepam-Dopamine Conjugates Increase Dopamine Delivery into Striatum of Intact Rats 44
Compromised decision-making and increased gambling proneness following dietary serotonin depletion in rats 44
Histamine-deficient mice do not respond to the antidepressant-like effects of oleoylethanolamide 44
Differential Effects of Palmitoylethanolamide against Amyloid-β Induced Toxicity in Cortical Neuronal and Astrocytic Primary Cultures from Wild-Type and 3xTg-AD Mice 43
Liver fat content assessed by conventional B-mode ultrasound and metabolic profile in non-diabetic patients: Implications for clinical practice 42
Depressive-like behavior is paired to monoaminergic alteration in a murine model of Alzheimer's disease 35
Psychosomatic syndromes are associated with IL-6 pro-inflammatory cytokine in heart failure patients 34
Lung histopathological findings in COVID-19 disease - a systematic review 32
Genetic Polymorphisms and Clinical Features in Diabetic Patients With Fatty Liver: Results From a Single-Center Experience in Southern Italy 31
The glucose metabolic pathway as a potential target for therapeutics: Crucial role of glycosylation in alzheimer’s disease 30
The GLP-1 receptor agonist Exendin-4 modulates hippocampal NMDA-receptor signalling in aged rats and improves cognitive impairment in diabetic elderly patients 28
The dual role of glutamatergic neurotransmission in Alzheimer’s disease: From pathophysiology to pharmacotherapy 28
Chronic Oral Palmitoylethanolamide Administration Rescues Cognitive Deficit and Reduces Neuroinflammation, Oxidative Stress, and Glutamate Levels in A Transgenic Murine Model of Alzheimer's Disease 27
Totale 6.834
Categoria #
all - tutte 29.155
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.155

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019174 0 0 0 0 0 0 0 0 0 22 42 110
2019/20201.371 244 165 55 17 183 184 227 29 100 20 125 22
2020/2021860 114 8 102 68 110 70 112 13 115 131 1 16
2021/2022538 64 11 4 8 39 14 12 38 89 76 30 153
2022/20232.350 202 96 96 158 115 230 39 194 1.104 23 46 47
2023/2024370 61 32 17 23 46 157 21 11 2 0 0 0
Totale 6.976